RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model

RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model

Abstract This study evaluated the clinical activity of RGN-259 (thymosin β4) in comparison with cyclosporine A (CsA), diquafosol (DQS), and lifitegrast (LFA) in a murine model of dry eye. The model was NOD.B10-H2 b mice in a 30–40% humidified environment together with daily scopolamine hydrobromide...

Full description

Bibliographic Details
Main Authors: Chae Eun Kim, Hynda K. Kleinman, Gabriel Sosne, George W Ousler, Kyeongsoon Kim, Sinwook Kang, Jaewook Yang
Format: Article
Language:English
Published: Nature Publishing Group 2018-07-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-018-28861-5

Similar Items

Similar Items